Progress in respiratory virus vaccine development

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 4, 2011, Pages 527-540

  Schmidt, Alexander C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

clinical development; clinical trial; metapneumovirus; parainfluenza virus; respiratory syncytial virus; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALPHA VIRUS VECTOR; BBG 2NA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN PARAINFLUENZA VIRUS 1 VACCINE; HUMAN PARAINFLUENZA VIRUS 2 VACCINE; HUMAN PARAINFLUENZA VIRUS 3 VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; METAPNEUMOVIRUS VACCINE; PARAINFLUENZA VACCINE; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE; VIRUS VECTOR;

ANTIBODY TITER; ANTIGEN EXPRESSION; CYTOPATHOGENIC EFFECT; CYTOTOXIC T LYMPHOCYTE; DELETION MUTANT; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG MEGADOSE; FEEDING DISORDER; FEVER; HIGH RISK POPULATION; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; METAPNEUMOVIRUS; METAPNEUMOVIRUS INFECTION; MISSENSE MUTATION; NOSE CONGESTION; PARAINFLUENZA VIRUS; PARAINFLUENZA VIRUS 3; PARAINFLUENZA VIRUS INFECTION; PARAMYXOVIRUS; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PURPURA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; VIRAL BRONCHIOLITIS; VIRUS LIKE AGENT; VIRUS REPLICATION;

ADULT; AGED; ANIMALS; CHILD; DRUG DESIGN; HUMANS; INFANT; RESPIRATORY TRACT INFECTIONS; VIRAL VACCINES; VIRUS DISEASES;

EID: 80051970965     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1283289     Document Type: Review

References (120)

1. Nair H, Nokes D J., Gessner B D. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010 375 9725 1545-1555
2. Mathisen M, Strand T A., Sharma B N. et al. RNA viruses in community-acquired childhood pneumonia in semi-urban Nepal; a cross-sectional study. BMC Med 2009 7 35
3. Berkley J A., Munywoki P, Ngama M et al. Viral etiology of severe pneumonia among Kenyan infants and children. JAMA 2010 303 20 2051-2057
4. Falsey A R., Hennessey P A., Formica M A., Cox C, Walsh E E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005 352 17 1749-1759 (Pubitemid 40570923)
5. Black R E., Cousens S, Johnson H L. et al, Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010 375 9730 1969-1987
6. Olsen S J., Thamthitiwat S, Chantra S et al. Incidence of respiratory pathogens in persons hospitalized with pneumonia in two provinces in Thailand. Epidemiol Infect 2010 138 12 1811-1822
7. Falsey A R., Hennessey P A., Formica M A., Cox C, Walsh E E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005 352 17 1749-1759 (Pubitemid 40570923)
8. Falsey A R., Formica M A., Hennessey P A., Criddle M M., Sullender W M., Walsh E E. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006 173 6 639-643 (Pubitemid 43363805)
9. Walsh E E., Peterson D R., Falsey A R. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J Infect Dis 2007 195 7 1046-1051 (Pubitemid 46452111)
10. Lindsley W G., Blachere F M., Davis K A. et al. Distribution of airborne influenza virus and respiratory syncytial virus in an urgent care medical clinic. Clin Infect Dis 2010 50 5 693-698
11. Zhang L, Peeples M E., Boucher R C., Collins P L., Pickles R J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002 76 11 5654-5666 (Pubitemid 34517916)
12. Zhang L, Bukreyev A, Thompson C I. et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005 79 2 1113-1124 (Pubitemid 40053894)
13. Schaap-Nutt A, Scull M A., Schmidt A C., Murphy B R., Pickles R J. Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys. Vaccine 2010 28 15 2788-2798
14. Siezen C L., Bont L, Hodemaekers H M. et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes. Pediatr Infect Dis J 2009 28 4 333-335
15. Bloemers B L., van Furth A M., Weijerman M E. et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitisa prospective birth-cohort study. Pediatrics 2007 120 4 e1076-e1081 (Pubitemid 47549555)
16. Bradley J P., Bacharier L B., Bonfiglio J et al. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics 2005 115 1 e7-e14 (Pubitemid 43046257)
17. Okiro E A., Ngama M, Bett A, Cane P A., Medley G F., James Nokes D. Factors associated with increased risk of progression to respiratory syncytial virus-associated pneumonia in young Kenyan children. Trop Med Int Health 2008 13 7 914-926 (Pubitemid 351813519)
18. Tristram D A., Hicks W Jr, Hard R. Respiratory syncytial virus and human bronchial epithelium. Arch Otolaryngol Head Neck Surg 1998 124 7 777-783 (Pubitemid 28328812)
19. Johnson J E., Gonzales R A., Olson S J., Wright P F., Graham B S. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007 20 1 108-119 (Pubitemid 44967956)
20. DeVincenzo J P., Wilkinson T, Vaishnaw A et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010 182 10 1305-1314
21. Houben M L., Coenjaerts F E., Rossen J W. et al. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J Med Virol 2010 82 7 1266-1271
22. Sigurs N, Aljassim F, Kjellman B et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010 65 12 1045-1052
23. Hyvärinen M, Ruotsalainen M, Korppi M. Outcome after bronchiolitis depends on disease definition. Thorax 2011 66 3 266-267 author reply 267
24. Stein R T., Sherrill D, Morgan W J. et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999 354 9178 541-545 (Pubitemid 29381367)
25. Lukacs N W., Smit J J., Schaller M A., Lindell D M. Regulation of immunity to respiratory syncytial virus by dendritic cells, toll-like receptors, and notch. Viral Immunol 2008 21 2 115-122 (Pubitemid 351873371)
26. El Saleeby C M., Li R, Somes G W., Dahmer M K., Quasney M W., DeVincenzo J P. Surfactant protein A2 polymorphisms and disease severity in a respiratory syncytial virus-infected population. J Pediatr 2010 156 3 409-414
27. Rämet M, Korppi M, Hallman M. Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making? Pediatr Pulmonol 2011 46 2 101-110
28. Forton J T., Rowlands K, Rockett K et al. Genetic association study for RSV bronchiolitis in infancy at the 5q31 cytokine cluster. Thorax 2009 64 4 345-352
29. Puthothu B, Bierbaum S, Kopp M V. et al. Association of TNF-alpha with severe respiratory syncytial virus infection and bronchial asthma. Pediatr Allergy Immunol 2009 20 2 157-163
30. Kulkarni A B., Collins P L., Bacik I et al. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J Virol 1995 69 2 1261-1264
31. Telcian A G., Laza-Stanca V, Edwards M R. et al. RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+T cell nonspecific antiviral activity. J Infect Dis 2011 203 1 85-94
32. Kruijsen D, Bakkers M J., van Uden N O. et al. Serum antibodies critically affect virus-specific CD4+/CD8+T cell balance during respiratory syncytial virus infections. J Immunol 2010 185 11 6489-6498
33. Connors M, Kulkarni A B., Firestone C Y. et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+T cells. J Virol 1992 66 12 7444-7451
34. Connors M, Kulkarni A B., Collins P L. et al. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J Virol 1992 66 2 1277-1281
35. Cautivo K M., Bueno S M., Cortes C M., Wozniak A, Riedel C A., Kalergis A M. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection. J Immunol 2010 185 12 7633-7645
36. Moghaddam A, Olszewska W, Wang B et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006 12 8 905-907 (Pubitemid 44175141)
37. Welliver T P., Garofalo R P., Hosakote Y et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007 195 8 1126-1136 (Pubitemid 46543443)
38. Reed J L., Welliver T P., Sims G P. et al. Innate immune signals modulate antiviral and polyreactive antibody responses during severe respiratory syncytial virus infection. J Infect Dis 2009 199 8 1128-1138
39. Eick A, Karron R, Shaw J et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J 2008 27 3 207-212
40. Shinoff J J., O'Brien K L., Thumar B et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 2008 198 7 1007-1015
41. Watt P J., Robinson B S., Pringle C R., Tyrrell D A. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 1990 8 3 231-236 (Pubitemid 20198855)
42. Plotnicky-Gilquin H, Cyblat-Chanal D, Aubry J P. et al. Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment. J Virol 2002 76 20 10203-10210
43. Walsh E E., Falsey A R. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004 190 2 373-378 (Pubitemid 38951980)
44. Smith C B., Purcell R H., Bellanti J A., Chanock R M. Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med 1966 275 21 1145-1152
45. Malley R, DeVincenzo J, Ramilo O et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998 178 6 1555-1561 (Pubitemid 28558122)
46. Lagos R, DeVincenzo J P., Muñoz A et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J 2009 28 9 835-837
47. Hall C B., Walsh E E., Long C E., Schnabel K C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991 163 4 693-698
48. Henderson F W., Collier A M., Clyde W A. Jr, Denny F W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979 300 10 530-534 (Pubitemid 9167827)
49. Wright P F., Karron R A., Madhi S A. et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 2006 193 4 573-581 (Pubitemid 43202749)
50. Karron R A., Wright P F., Belshe R B. et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005 191 7 1093-1104 (Pubitemid 40404368)
51. Karron R A., Belshe R B., Wright P F. et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003 22 5 394-405 (Pubitemid 36578739)
52. Williams J V., Weitkamp J H., Blum D L., LaFleur B J., Crowe J E. Jr. The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations. Mol Immunol 2009 47 2-3 407-414
53. Crowe J E. Jr. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis 2001 33 10 1720-1727
54. Crowe J E. Jr, Firestone C Y., Murphy B R. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 2001 167 7 3910-3918 (Pubitemid 32910836)
55. Kim H W., Canchola J G., Brandt C D. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969 89 4 422-434
56. Wright P F., Karron R A., Belshe R B. et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 2007 25 42 7372-7378 (Pubitemid 47484016)
57. Collins P L., Chanock R M., Murphy B R. Respiratory syncytial virus. In: Knipe D M. Howley P M. Griffin D E. et al, eds. Fields Virology. 4th ed. Philadelphia, PA Lippincott Williams & Wilkins 2001 1443-1486
58. Piedra P A. Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J 2003 22 2, Suppl S94-S99 (Pubitemid 36228159)
59. Piedra P A., Cron S G., Jewell A et al, Purified Fusion Protein Vaccine Study Group. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 2003 21 1920 2448-2460 (Pubitemid 36561336)
60. Munoz F M., Piedra P A., Glezen W P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003 21 24 3465-3467 (Pubitemid 36792104)
61. Kneyber M C., Kimpen J L. Advances in respiratory syncytial virus vaccine development. Curr Opin Investig Drugs 2004 5 2 163-170
62. Bartlett E J., Castaño A, Surman S R., Collins P L., Skiadopoulos M H., Murphy B R. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes. Virol J 2007 4 67
63. Nolan S M., Surman S R., Amaro-Carambot E, Collins P L., Murphy B R., Skiadopoulos M H. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine 2005 23 39 4765-4774 (Pubitemid 41557327)
64. McAuliffe J M., Surman S R., Newman J T. et al. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J Virol 2004 78 4 2029-2036 (Pubitemid 38176734)
65. Collins P L., Murphy B R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc 2005 2 2 166-173 (Pubitemid 41233386)
66. Bukreyev A, Belyakov I M., Berzofsky J A., Murphy B R., Collins P L., Schmidt A C. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J Virol 2001 75 24 12128-12140 (Pubitemid 33115886)
67. Bukreyev A, Lamirande E W., Buchholz U J. et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004 363 9427 2122-2127 (Pubitemid 38844152)
68. Bartlett E J., Amaro-Carambot E, Surman S R. et al. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 2005 23 38 4631-4646 (Pubitemid 41132813)
69. Bartlett E J., Amaro-Carambot E, Surman S R., Collins P L., Murphy B R., Skiadopoulos M H. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates. Vaccine 2006 24 14 2674-2684 (Pubitemid 43290400)
70. Bartlett E J., Cruz A M., Esker J et al. Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. J Virol 2008 82 18 8965-8977
71. Schaap-Nutt A, Higgins C, Amaro-Carambot E et al. Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates. J Virol 2011 85 8 4007-4019
72. Boonyaratanakornkit J, Bartlett E, Schomacker H et al. The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger MDA5 and protein kinase R. J Virol 2011 85 4 1495-1506
73. Roldão A, Mellado M C., Castilho L R., Carrondo M J., Alves P M. Virus-like particles in vaccine development. Expert Rev Vaccines 2010 9 10 1149-1176
74. Jennings G T., Bachmann M F. The coming of age of virus-like particle vaccines. Biol Chem 2008 389 5 521-536 (Pubitemid 351874198)
75. Atkins G J., Fleeton M N., Sheahan B J. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 2008 10 e33
76. Hubby B, Talarico T, Maughan M et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 2007 25 48 8180-8189 (Pubitemid 350046318)
77. Kamrud K I., Custer M, Dudek J M. et al. Alphavirus replicon approach to promoterless analysis of IRES elements. Virology 2007 360 2 376-387 (Pubitemid 46486674)
78. Thompson J M., Nicholson M G., Whitmore A C. et al. Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. J Immunol 2008 181 1 574-585
79. Tonkin D R., Jorquera P, Todd T, Beard C W., Johnston R E., Barro M. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 2010 28 18 3238-3246
80. Mok H, Lee S, Utley T J. et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol 2007 81 24 13710-13722 (Pubitemid 350247864)
81. Bernstein D I., Reap E A., Katen K et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009 28 2 484-493
82. Peiperl L, Morgan C, Moodie Z et al, NIAID HIV Vaccine Trials Network. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS ONE 2010 5 10 e13579
83. Jaoko W, Karita E, Kayitenkore K et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS ONE 2010 5 9 e12873
84. Song K, Bolton D L., Wei C J. et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc Natl Acad Sci U S A 2010 107 51 22213-22218
85. Dudareva M, Andrews L, Gilbert S C. et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009 27 27 3501-3504
86. Ersching J, Hernandez M I., Cezarotto F S. et al. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology 2010 407 1 1-6
87. Buchbinder S P., Mehrotra D V., Duerr A et al, Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008 372 9653 1881-1893
88. Graham B S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011 239 1 149-166
89. Graham B. Gene-based vector vaccines for respiratory syncytial virus. Paper presented at: 7th International RSV Symposium; December 4, 2010; Rotterdam, The Netherlands
90. Langley J M., Sales V, McGeer A et al. A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults >or =65 years of age. Vaccine 2009 27 42 5913-5919
91. Falsey A R., Walsh E E., Capellan J et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccinesnonadjuvanted vaccine or vaccine adjuvanted with alumgiven concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 2008 198 9 1317-1326
92. Wright P F., Karron R A., Belshe R B. et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000 182 5 1331-1342
93. Collins P L., Hill M G., Camargo E, Grosfeld H, Chanock R M., Murphy B R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5 proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A 1995 92 25 11563-11567
94. Jin H, Zhou H, Cheng X, Tang R, Munoz M, Nguyen N. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 2000 273 1 210-218 (Pubitemid 30602023)
95. Teng M N., Whitehead S S., Bermingham A et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 2000 74 19 9317-9321
96. McGinnes L W., Gravel K A., Finberg R W. et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 2011 85 1 366-377
97. Murawski M R., McGinnes L W., Finberg R W. et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 2010 84 2 1110-1123
98. Pantua H D., McGinnes L W., Peeples M E., Morrison T G. Requirements for the assembly and release of Newcastle disease virus-like particles. J Virol 2006 80 22 11062-11073 (Pubitemid 44706547)
99. Skiadopoulos M H., Surman S, Tatem J M. et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 1999 73 2 1374-1381 (Pubitemid 29036792)
100. Belshe R B., Newman F K., Tsai T F. et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 2004 189 3 462-470 (Pubitemid 38210583)
101. Belshe R B., Newman F K., Anderson E L. et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis 2004 190 12 2096-2103 (Pubitemid 39636356)
102. Bernstein D, Charenkavanich S, Falloon J. Safety profile, immunogenicity, and viral shedding of rHPIV3cp45, a live, attenuated human parainfluenzavirus type 3 (PIV3) vaccine. Paper presented at: 7th International RSV Symposium; December 4, 2010; Rotterdam, The Netherlands
103. van Wyke Coelingh K L., Winter C C., Tierney E L., London W T., Murphy B R. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J Infect Dis 1988 157 4 655-662 (Pubitemid 18093723)
104. Karron R A., Makhene M, Gay K, Wilson M H., Clements M L., Murphy B R. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 1996 15 8 650-654 (Pubitemid 26271970)
105. Greenberg D P., Walker R E., Lee M S. et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis 2005 191 7 1116-1122 (Pubitemid 40404370)
106. Schmidt A C., McAuliffe J M., Huang A et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 2000 74 19 8922-8929
107. Tang R S., MacPhail M, Schickli J H. et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 2004 78 20 11198-11207 (Pubitemid 39299659)
108. Tang R S., Spaete R R., Thompson M W. et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 2008 26 50 6373-6382
109. Schmidt A C., McAuliffe J M., Murphy B R., Collins P L. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 2001 75 10 4594-4603 (Pubitemid 32381501)
110. Schmidt A C., Wenzke D R., McAuliffe J M. et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 2002 76 3 1089-1099 (Pubitemid 34066413)
111. Gomez M, Mufson M A., Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J 2009 28 7 655-658
112. Bernstein D, Malkin E, Charenkavanich S, Dubovsky F. Safety profile, immunogenicity, and viral shedding of MEDI-534, a live, attenuated respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine in RSV/PIV3 seronegative children. Paper presented at: 7th International RSV Symposium; December 4, 2010; Rotterdam, The Netherlands
113. Biacchesi S, Pham Q N., Skiadopoulos M H., Murphy B R., Collins P L., Buchholz U J. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol 2005 79 19 12608-12613 (Pubitemid 41346125)
114. Buchholz U J., Nagashima K, Murphy B R., Collins P L. Live vaccines for human metapneumovirus designed by reverse genetics. Expert Rev Vaccines 2006 5 5 695-706 (Pubitemid 46021050)
115. Pham Q N., Biacchesi S, Skiadopoulos M H., Murphy B R., Collins P L., Buchholz U J. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol 2005 79 24 15114-15122 (Pubitemid 43032294)
116. Newman J T., Riggs J M., Surman S R. et al. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. J Virol 2004 78 4 2017-2028 (Pubitemid 38176733)
117. Van Cleve W, Amaro-Carambot E, Surman S R. et al. Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1. Virology 2006 352 1 61-73 (Pubitemid 44164412)
118. Boonyaratanakornkit J B., Bartlett E J., Amaro-Carambot E, Collins P L., Murphy B R., Schmidt A C. The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection. J Virol 2009 83 4 1892-1910
119. Nolan S M., Surman S R., Amaro-Carambot E, Collins P L., Murphy B R., Skiadopoulos M H. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine 2005 23 39 4765-4774 (Pubitemid 41557327)
120. Nolan S M., Skiadopoulos M H., Bradley K et al. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3 genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates. Vaccine 2007 25 34 6409-6422 (Pubitemid 47096752)